DGAP-News: BRAIN Biotech AG / Key word(s): Personnel
Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasons
Prof. Hauer has been a member of the Supervisory Board of BRAIN Biotech AG since March 2019.
The search for a successor to Prof. Hauer will be initiated by the Supervisory Board and it is intended to present a suitable candidate to the shareholders for election at the Annual General Meeting for the current fiscal year 2021/22.
The Chairman of the Supervisory Board of BRAIN Biotech AG, Dr. Georg Kellinghusen, expresses his special thanks to Prof. Dr. Hauer: "Bernhard is a much respected scientist and has always enriched the discussions in the Supervisory Board with his expertise as well as his personality. I thank him for his commitment to BRAIN Biotech AG and wish him every success for his private and professional future – also on behalf of my Supervisory Board colleagues and the entire Management Board."
BRAIN Biotech AG (“BRAIN”) is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products, BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success.
BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group.
As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. Our products and services target at least five of the UN SDGs directly.
Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
Contact Investor Relations
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.
Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.
BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.
30.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
BRAIN Biotech AG
Darmstädter Straße 34-36
+49 (0) 62 51 / 9331-0
+49 (0) 62 51 / 9331-11
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:
End of News
DGAP News Service